Taysha Gene Therapies’ (TSHA) Buy Rating Reiterated at Needham & Company LLC

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “buy” rating reiterated by equities researchers at Needham & Company LLC in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $7.00 price target on the stock. Needham & Company LLC’s price target points to a potential upside of 212.50% from the stock’s current price.

A number of other equities research analysts have also recently weighed in on TSHA. Cantor Fitzgerald restated an “overweight” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, June 20th. Jefferies Financial Group restated a “buy” rating and issued a $8.00 price target (up previously from $2.00) on shares of Taysha Gene Therapies in a research note on Tuesday, May 14th. Chardan Capital reiterated a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, June 18th. JMP Securities reissued a “market outperform” rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a report on Thursday, June 20th. Finally, Piper Sandler lowered their price target on Taysha Gene Therapies from $9.00 to $7.00 and set an “overweight” rating for the company in a research report on Monday, July 1st. Ten research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $6.60.

Taysha Gene Therapies Price Performance

TSHA stock opened at $2.24 on Tuesday. The stock has a market capitalization of $418.92 million, a price-to-earnings ratio of -4.57 and a beta of 0.41. The firm’s 50-day moving average price is $2.89 and its two-hundred day moving average price is $2.49. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.75. Taysha Gene Therapies has a 12-month low of $0.62 and a 12-month high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.01. Taysha Gene Therapies had a negative net margin of 833.60% and a negative return on equity of 782.81%. The business had revenue of $3.41 million during the quarter, compared to analyst estimates of $3.70 million. During the same period in the prior year, the business earned ($0.28) EPS. As a group, equities analysts predict that Taysha Gene Therapies will post -0.41 earnings per share for the current year.

Insider Buying and Selling at Taysha Gene Therapies

In other news, major shareholder Paul B. Manning bought 1,333,333 shares of Taysha Gene Therapies stock in a transaction that occurred on Thursday, June 27th. The stock was bought at an average price of $2.25 per share, for a total transaction of $2,999,999.25. Following the purchase, the insider now directly owns 1,333,333 shares of the company’s stock, valued at approximately $2,999,999.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Howard Capital Management Inc. purchased a new stake in shares of Taysha Gene Therapies in the fourth quarter valued at about $25,000. Victory Capital Management Inc. purchased a new stake in shares of Taysha Gene Therapies in the 4th quarter valued at approximately $28,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Taysha Gene Therapies during the 4th quarter worth approximately $31,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Taysha Gene Therapies during the 4th quarter valued at approximately $38,000. Finally, Cannon Global Investment Management LLC acquired a new position in Taysha Gene Therapies in the first quarter valued at approximately $69,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.